Partnering

We continue to invest in our pipeline and aim to add considerably to our portfolio over the next few years – in April 2019, we acquired the international rights to two new niche established medicines. We have plans for more.

We have a proud heritage and successful track record of business and product acquisitions and company assets around the world, including BNM in Australia, Focus Pharmaceuticals in the UK, and Abcur in the Nordics.

We pride ourselves on our close working relationship with our manufacturing partners and have a well-established, international distribution network, working with over 75 CMOs, the majority of whom are based in Europe.

Where possible, we seek partners who can provide a wide range of services that complement our supply such as technical and regulatory expertise.

Our virtual operating model combined with regulatory, quality and supply-chain functions, a commercial platform in almost 100 countries and a solid track record in selling and marketing products in these countries means we can acquire and integrate new products and companies quickly and efficiently.

As part of our drive to enhance our commercial capabilities in W. Europe, we have bolstered our commercial footprint in these strategic markets through the addition of global brand and market access roles to build a direct presence.

We have a sustainable business, and our operating expenditure is probably one of the leanest and lowest in the sector, combined with a new board and leadership team and our global niche established medicines platform, we believe we are well positioned to execute on our goals.

With a new board and leadership team and our global niche established medicines platform, we believe we are well positioned to execute on our goals.